NCT02082210 2020-12-19
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Completed
Clinical Trials
5 trialsNCT01900652 2019-09-18
Chime
Eli Lilly and Company
Phase 2 Completed
NCT01287546 2017-02-15
A Study of LY2875358 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01602289 2015-06-08
A Study of LY2875358 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01874938 2015-01-16
A Study of LY2875358 in Participants With MET Positive, Advanced Gastric Cancer
Eli Lilly and Company
Phase 2 Completed